Register to chat with like-minded investors on our interactive forums.

Get Started

Home
Investing
Stocks
USA
NASDAQ
Dare Bioscience Inc (DARE)
Dare Bioscience Inc (DARE) News

DARE

Dare Bioscience (DARE)

Dare Bioscience Inc

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:DARE

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next >>

Date	Time	Source	Headline	Symbol	Company
03/01/2023	8:00AM	GlobeNewswire Inc.	Daré Bioscience to Present at the 35th Annual Roth Conference	NASDAQ:DARE	Dare Bioscience Inc
02/22/2023	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1	NASDAQ:DARE	Dare Bioscience Inc
02/06/2023	8:02AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
02/01/2023	8:00AM	GlobeNewswire Inc.	Daré Bioscience to Participate in Three February Conferences	NASDAQ:DARE	Dare Bioscience Inc
01/27/2023	5:16PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
01/26/2023	4:07PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:DARE	Dare Bioscience Inc
01/26/2023	4:07PM	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:DARE	Dare Bioscience Inc
01/26/2023	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms	NASDAQ:DARE	Dare Bioscience Inc
01/25/2023	8:01AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
01/09/2023	8:07AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
01/09/2023	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vaginal Symptoms of Menopause	NASDAQ:DARE	Dare Bioscience Inc
12/16/2022	5:11PM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
12/12/2022	8:06AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
12/12/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea	NASDAQ:DARE	Dare Bioscience Inc
12/05/2022	7:46AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
11/15/2022	1:15PM	TipRanks	Maxim Group Sticks to Its Buy Rating for Daré Bioscience (DARE)	NASDAQ:DARE	Dare Bioscience Inc
11/15/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health	NASDAQ:DARE	Dare Bioscience Inc
11/15/2022	6:15AM	TipRanks	Daré Bioscience (DARE) Receives a Buy from H.C. Wainwright	NASDAQ:DARE	Dare Bioscience Inc
11/14/2022	8:06AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
11/14/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study	NASDAQ:DARE	Dare Bioscience Inc
11/11/2022	6:35AM	TipRanks	H.C. Wainwright Reaffirms Their Buy Rating on Daré Bioscience (DARE)	NASDAQ:DARE	Dare Bioscience Inc
11/10/2022	4:06PM	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:DARE	Dare Bioscience Inc
11/10/2022	6:01AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc
11/10/2022	5:45AM	GlobeNewswire Inc.	Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update	NASDAQ:DARE	Dare Bioscience Inc
11/08/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience to Present at the Stifel 2022 Healthcare Conference	NASDAQ:DARE	Dare Bioscience Inc
11/03/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022	NASDAQ:DARE	Dare Bioscience Inc
11/01/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete	NASDAQ:DARE	Dare Bioscience Inc
10/18/2022	6:21AM	TipRanks	Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Daré Bioscience (DARE) and COMPASS Pathways (CMPS)	NASDAQ:DARE	Dare Bioscience Inc
10/17/2022	8:00AM	GlobeNewswire Inc.	Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study	NASDAQ:DARE	Dare Bioscience Inc
10/11/2022	9:01AM	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:DARE	Dare Bioscience Inc

Showing the most relevant articles for your search:NASDAQ:DARE

<< Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next >>

Globestar Therapeutics (PK)

Emergent Health (PK)

Golden Triangle Ventures (PK)

Kraig Biocraft Laborator... (QB)

Therapeutic Solutions (PK)

Elite Pharmaceuticals (QB)

Virexit Technologies (PK)

Cann American (CE)

Code Green Apparel (PK)

TPT Global Tech (PK)

RespireRx Pharmaceuticals (PK)

SMC Entertainment (PK)

Bioelectronics (PK)

Delayed Upgrade Clock